Compare AIV & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIV | DSGN |
|---|---|---|
| Founded | 1975 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 837.1M | 819.6M |
| IPO Year | 1996 | 2021 |
| Metric | AIV | DSGN |
|---|---|---|
| Price | $4.24 | $14.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $10.00 | ★ $15.25 |
| AVG Volume (30 Days) | ★ 1.3M | 493.9K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | ★ 87.41% | N/A |
| EPS Growth | ★ 616.00 | N/A |
| EPS | ★ 3.87 | N/A |
| Revenue | ★ $138,486,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.12 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.94 | $3.11 |
| 52 Week High | $8.87 | $17.25 |
| Indicator | AIV | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 49.44 | 59.24 |
| Support Level | $4.03 | $9.71 |
| Resistance Level | $4.28 | $17.25 |
| Average True Range (ATR) | 0.06 | 1.16 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 45.16 | 42.56 |
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment; Operating, and Other. Development and Redevelopment segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. Operating segment includes 20 residential apartment communities with 5,243 apartment homes that have achieved a stabilized level of operations. Other segment includes The Benson Hotel, company's only hotel. Majority of revenue is gained from Operating Segment.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.